The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

LOS ANGELES (KABC) -- We know untreated high cholesterol could lead to heart disease or stroke and statins are usually the gold standard treatment. However, not everyone can take them. Now, Cleveland ...

An experimental gene therapy for high cholesterol is showing promise in clinical trials and inching closer to approval. The treatment, called VERVE-102, is being tested in people with familial ...

MANNHEIM, Germany—New international data paint a very dire outlook for patients with homozygous familial hypercholesterolemia (HoFH), with investigators reporting that more than half of deaths that ...

The prevalence of elevated low-density lipoprotein cholesterol (LDL-C) has declined over the past two decades, but 1 in 17 Americans still have a level of 160-189 mg/dL, and 1 in 48 have a level ≥ 190 ...

Nearly 94 million Americans over the age of 20—which is approximately 40% of the U.S. population—have high cholesterol, reports the Centers for Disease Control and Prevention (CDC). The major risk ...

An expert discusses how primary and secondary prevention differ in atherosclerotic cardiovascular disease, with secondary ...

Personalized medicine is transforming heart care by shifting cholesterol management from generic levels to precise risk ...

Please provide your email address to receive an email when new articles are posted on . Inclisiran is now FDA approved as monotherapy for LDL reduction. The drug is no longer required to be used on ...

An experimental gene therapy for high cholesterol is showing promise in clinical trials and inching closer to approval. The treatment, called VERVE-102, is being tested in people with familial ...